C4#Laboratories,#LLC Suite#B202

Dear Valued Colleague,

C4 Laboratories, LLC

1930 S. Alma School Rd

Suite B202

Mesa, AZ 85210



"Patient protection through true science"

Thank you for selecting C4 Laboratories. Our goal at C4 is to provide reliable data that is interpreted within the appropriate physiological context, to ultimately empower patients to use cannabis medicine more effectively.

The data within this report are the result of various analytical methods that have been developed by the team of scientists at C4 Laboratories. For the characterization and quantification of 21 terpene compounds and residual solvents we use Head--Space Gas Chromatography with Flame Ionization Detection (HS--GC--FID). Additionally, Ultra High Performance Liquid Chromatography (UHPLC) is used for the characterization and quantification of the 10 major phytocannabinoids found in cannabis. All data are collected in concert with proper quality assurance/quality control measures (QA/QC), including the use of intermittent analytical blanks, sample spikes, and commercial standards.

As an additional measure of quality control, we provide a historical reference (when available) to analytical results from an equivalent strain of cannabis/cannabis product to draw comparison. We understand that within an individual strain that results may vary as a result of variances in sample homogeniety, analytical

InfomrmethoEdnolvogiryo, cnromp ceonndtaitilo,nLs,L geCnetic drift, and/or gene flow during hybridization. However, such a

6060 N. Central Expressway Suite 500

Dallasc, oTemxapsa7r5is2o06n can provide valuable insight into sample integrity and/or the phenotypic identity of the analyzed sample. Phone: 915-694-7132

E-Mail: zac@;

Additionally, we have interpreted all data within the physiological context provided to us by the growing

ruitt

Meander Rd, Gboradnyb ourfy p, eTeerx-a-rsev7i6e0w49ed scientific research studies. Key factors to consider when determing how to most 999-7931 appropriately use a particular strain of cannabis include, but are not limited to, an evaluation of the possible

t@

cannabinoid/terpene synergies and an analysis of the various cannabinoid ratios, particular the CBD--A/THC--

A and CBG/CBN ratios.

Mr. Pruitt,

Within this rIetp iosr itmyopuorwtiallnftin tdoi nntoetrper tehtaattio wnsheonf t ahenawlyazteinrgq ucaalnitnyadbaitsa trheesruelt i cnagnfr eoxmistth neatural variablity of cannabinoid and

ses of your wteellrwpeanteer cpoenrfcoermnterdatbiyonTsT wI Eitnhviniro innmdievnidtaul aLla pbloarnattso.r i Cesa.nTnhaebisnaomidp lceosnwceenretrations in cannabis flower have been

rved ction

aAngdenpcryepfo(aEurePndAd) a . tosB iprnieecrfrlyem,aesdteeh to dedicsottilooangllyya wanpditphrqo ruveaesndptiefbiccyat t ttihooen thUoefn irtvoeodolatSt milteaatesassn.d EAnssv e simurocin-hvm,o etlahntetiale lanalysis of multiple samples from any

ounds was peprfloarnmte odf uinstinegreEstP Ais rmeectohmodm8e2n6d0eBd. .Additionally, the quantification of metal

es and water anions was performed using EPA methods 200.7 and 300A, respectively. All

minations were executed using EPA approved methods and the resulting data has

rgone a thorouTghharnevki e ywoua n adgaisind efoerm yeoduarc ccounraftiedeanncdec oinm Cp4le tLea.boratories. We strive to be an authority on cannabis education,

u have any quteasrtgioentsedab tohuetrathpeiewsa atnerdq puaatliiteyndt a ptraoatencdt/oiornth. eAlisnote, r apsre ata rteiosnesarocfht h laebdoartaat,ory, we hope to discover novel e do not hesitactaentnoacboinst a ccotnusstiatut zeanct@ s tinhfroorumgehn v o.cuorm efofor r9t1s5 w-6i9th4- a71ca3d2.emic research programs in the C4 Cannabinomics

Collaborative. For more information about how you can collaborate with our research team please visit our

website at .

Zacariah L. Hildenbrand, Ph.D. Chief Scientific Officer C4 Laboratories, LLC

Zacariah L. Hildenbrand, Ph.D. Chief Technology Officer

PRODUCT SUMMARY

ID: EC_DCBD1_121715

Analyte: Flower

Strain: DCBD1

Client: Errl Cup

Date: 12/17/15

Microbial Screen: PASS

Foreign Material: PASS

Pesticide Analysis: Not performed

Residual Solvents: Not performed

Major 10 Cannabinoids:

23.78%

Total available THC:

8.28%

Total THC Isomers:

8.28% 9 + 8 THC

Total available CBD:

12.06%

Highest Terpenes: Not performed

Not performed

Not performed

Activated THC: 0.000 (mg)

APPLICABLE TO MEDIBLES, TINCTURES AND SALVES

Fresh product (CBG/CBN):

0.00

CBG/CBN > 1.0 denotes fresh product, CBG/CBN < 1.0 denotes high CBN strain and/or an oxidized product

Targeted Use: Modulates THC--induced psychoactivity (CBD), anti--inflammatory and analgesic (THC),

appetite stimulant (CBN), antibacterial and antifungal (CBC)

Potency Profile CBDV

CBD--A

Value (%) 0.00

13.75

Historical (%)

Therapeutic properties

#N/A #N/A

Not detected.

See therapeutic properties of CBD for medicinal value upon activation through decarboxylation

CBG

Not detected.

0.00

#N/A

CBD

Not detected.

0.00

#N/A

THCV CBN 9--THC

Not detected.

0.00

#N/A

Appetite stimulant (Farrimond et al., 2012), analgesic

(Zygmunt et al., 2002) and anti--tumorigenic against some

0.39

#N/A forms of lung cancer (BiFulco et al., 2006)

Anti--inflammatory and analgesic (Russo, 2011),

neuroprotectant (Hampson et al., 1999), reduces intraocular

pressure associated with glaucoma, spasticity and muscle

1.06

#N/A tension (Pacher et al., 2006)

8--THC

0.00

CBC

9--THC--A

Total Available THC Total THC Isomers Total Available CBD CBD/9--THC ratio

CBG/CBN ratio

0.35

8.23

8.28 8.28 12.06 1.457 0.00

#N/A

#N/A #N/A #N/A #N/A #N/A #N/A #N/A

Not detected.

Antibacterial and antifungal (ElSohly et al., 1982), anti-- inflammatory (Izzo et al., 2012; Delong et al., 2010), antidepressant (El--Alfy et al., 2010; Deyo and Musty, 2003), and stimulates bone and nerve growth (Shingyo and Di Marzo, 2013) See therapeutic properties of 9--THC for medicinal value upon activation through decarboxylation

General Characteristics 9--THC--A + 9--THC (accounts for conversion rate) 9--THC--A + 9--THC + 8--THC (accounts for conversion rate) CBD--A + CBD (accounts for conversion rate) CBD--dominant, non--psychoactive CBG/CBN > 1.0 denotes fresh product, CBG/CBN < 1.0 denotes high CBN strain and/or an oxidized product

Major 10 Total

23.78

#N/A #N/A

Historical measurements based on analysis of equivalent product

N/A

Blank cells denote cannabinoid concentrations below the limit of detection (0.01%)

#N/A

Terpene Profile alpha--Pinene

Camphene beta--Pinene beta--Myrcene delta--3--Carene alpha--Terpinene p--Cymene

Value (%) Historical (%)

0.000

0.000

0.000

0.000 0.000 0.000 0.000

#N/A

#N/A

#N/A

#N/A #N/A #N/A #N/A

Not detected. Not detected. Not detected. Not detected. Not detected. Not detected.

Therapeutic properties

d--Limonene

Ocimene gamma--Terpinene

Terpinolene

0.000

0.000 0.000 0.000

#N/A

#N/A #N/A #N/A

Not detected.

Not detected. Not detected. Not detected.

Linalool (--)--Isopulegol

Geraniol

0.000 0.000

0.000

#N/A #N/A

#N/A

Not detected. Not detected. Not detected.

beta--Caryophyllene alpha--Humulene

0.000 0.000

#N/A #N/A

Not detected. Not detected.

Nerolidol Guaiol

(--)--alpha--Bisabolol

0.000 0.000 0.000

#N/A #N/A #N/A

Not detected. Not detected. Not detected.

Eucalyptol (--)--Caryophyllene oxide

Terpene Total

0.000

0.000 0.000

#N/A

#N/A #N/A

Not detected. Not detected. #N/A

* Based on historical measurements of equivalent strain/product Blank cells denote terpene concentrations below the limit of detection (0.001%)

Cannabinoid Ratios CBD--A/9--THC--A ratio is within the optimal therapeutic range of 1--2 (Lemberger et al., 1976; Burnett, 2014) CBD--A/9--THC--A ratio is above 1, user is less likely to experience tachycardia (increased heart rate) and difficulty walking, which can result from THC ingestion (Burnett, 2014) CBG/CBN > 1.0 denotes fresh product and is useful for the treatment of gastrointestinal abnormalities (Borrelli et al., 2013), CBG/CBN < 1.0 denotes high CBN strain and/or an oxidized product

Cannabinoid/Terpene Synergies (Russo, 2011)

Additional Observations Terpene analysis was not performed Residual Solvents Not performed Pesticides Not performed

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download